Drug intelligence / Profile preview

Yuhudie Quban Cream

Development stage: Unknown
Lead developer: Hangzhou Qianjin Pharmaceutical
Administration: Topical

Overview

Yuhudie Quban Cream is a topical Traditional Chinese Medicine (TCM) formulation developed by Hangzhou Qianjin Pharmaceutical for the treatment of melasma. It is specifically designed for adult patients with stable centrofacial melasma presenting with the qi stagnation and blood stasis pattern. The formulation is based on traditional herbal ingredients, likely including Oroxylum indicum (Yuhudie), intended to address hyperpigmentation and improve skin condition through topical application. It is currently undergoing Phase IIb exploratory clinical trials in China to evaluate its efficacy and safety.

Brand names: Yuhudie Quban Cream
Other names: Yuhudie Melasma Cream

Targets

TYR (Tyrosinase)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)

Beyond the preview

Go deeper on Yuhudie Quban Cream.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yuhudie Quban Cream.

Explore the full profile